Skip to content
›

Provincial Specialty Alliance Carries Forward TCM Expertise in Treating Atrial Fibrillation

Against the backdrop of the national deep implementation of the “Healthy China” strategy, on March 28, 2026, the “Hebei Provincial Cardiovascular Specialty Provincial TCM Advantage Alliance” was officially inaugurated, led by the Cardiovascular Department of Hebei Yiling Hospital. The establishment of this alliance aims to fully leverage the exemplary and radiating role of high-quality TCM cardiovascular medical resources, effectively enhancing the TCM prevention and treatment capabilities for cardiovascular diseases within the region.

As the leading unit of the alliance, the Cardiovascular Department of Hebei Yiling Hospital has long been dedicated to integrated Chinese and Western medicine diagnosis and treatment of major cardiovascular diseases. This confidence stems not only from a top-tier expert team and advanced hardware facilities but also from a series of patented new drugs and distinctive in-house preparations developed through long-term clinical practice guided by the collateral-disease theory. Among these, the innovative preparation Tongbu Fangzhan Granules, a core specialty medication for solving the challenges of atrial fibrillation (AF) treatment, vividly reflects the department’s academic depth and clinical strength.

Addressing Clinical Challenges and Breaking Treatment Limitations

Atrial fibrillation is the most common arrhythmia encountered clinically, severely impacting patients’ quality of life and significantly increasing the risk of complications such as stroke and heart failure. Currently, conventional antiarrhythmic drug therapies have limited effectiveness for some patients and may cause adverse effects with long-term use; radiofrequency ablation surgery also has a relatively high recurrence rate and is often accompanied by residual symptoms such as palpitations and chest tightness. Faced with these fragmented intervention limitations, there is an urgent need for an intervention strategy that can regulate the condition holistically.

Relying on a profound foundation in collateral-disease theory, the Cardiovascular Department of Hebei Yiling Hospital precisely identifies “zong qi deficiency and collateral deficiency” as the fundamental cause of AF, with “stagnant deficient qi and internal wind disturbing the collaterals” as the key pathological mechanism. Based on this, the department developed Tongbu Fangzhan Granules, composed of 14 Chinese herbs including Huangqi (Astragalus), fried Suanzaoren (Ziziphus seed), and Shanzhuyu (Cornus officinalis), establishing the treatment principle of “unblocking and tonifying collateral deficiency, extinguishing wind and calming palpitations.” This formula not only promotes blood circulation, regulates qi, and disperses blood stasis but also tonifies qi and raises yang, calms the mind, and relieves vexation, thereby improving patients’ overall condition from multiple dimensions.

Solid Clinical Evidence Supporting Whole-Cycle Management Tongbu Fangzhan Granules are not merely a single “anti-arrhythmia” medication but an integrated regulatory “tool” throughout the entire management cycle of atrial fibrillation.

· Multi-target Anti-remodeling: Animal studies have found that this formula exerts comprehensive effects on three critical aspects: electrical signals, cardiac structure, and neural regulation, effectively reducing the risk of AF episodes.

· Significant Reduction in Recurrence: Clinical controlled trials show that when combined with standardized Western medical treatment for three months, the recurrence rate of AF is reduced by 50% compared to Western medicine alone; the frequency of episodes decreases by 65% compared to before treatment, and the average time to recurrence is extended by approximately 45 days.

· Improvement of Clinical Symptoms: Beyond paroxysmal AF, Tongbu Fangzhan Granules also demonstrate efficacy in persistent AF and in preventing AF recurrence after radiofrequency ablation. Whether as a conservative treatment for non-surgical patients or for post-ablation recurrence prevention, it effectively alleviates symptoms such as palpitations, shortness of breath, fatigue, insomnia, and vivid dreams, significantly enhancing quality of life.

With the official launch of the Provincial TCM Cardiovascular Advantage Specialty Alliance, Hebei Yiling Hospital will collaborate closely with alliance members to vigorously promote the homogenization and improvement of cardiovascular disease medical quality, providing higher-quality, more systematic whole-cycle health management services for AF patients across the province and beyond.

Related reading